RS51018B - Farmaceutska kompozicija inhibitora pde4 ili inhibitora pde3/4 i antagoniste histamiinskih receptora - Google Patents

Farmaceutska kompozicija inhibitora pde4 ili inhibitora pde3/4 i antagoniste histamiinskih receptora

Info

Publication number
RS51018B
RS51018B YUP-780/04A YUP78004A RS51018B RS 51018 B RS51018 B RS 51018B YU P78004 A YUP78004 A YU P78004A RS 51018 B RS51018 B RS 51018B
Authority
RS
Serbia
Prior art keywords
pharmaceutical composition
pde3
pde4
inhibitor
receptor antagonist
Prior art date
Application number
YUP-780/04A
Other languages
English (en)
Inventor
Christian Weimar
Daniela Bundschuh
Rolf Beume
Stefan-Lutz Wollin
Original Assignee
Nycomed Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh. filed Critical Nycomed Gmbh.
Publication of RS78004A publication Critical patent/RS78004A/sr
Publication of RS51018B publication Critical patent/RS51018B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Farmaceutska kompozicija, naznačena time, što se sastoji od smeše prve aktivne supstance, koja je odabrana iz grupe koja se sastoji od 3-ciklopropilmetoksi-4-difluorometoksi-N-(3,5-dihloropirid-4-il)-benzamida [INN: ROFLUMILAST], (-)-cis-9-etoksi-8-metoksi-2-metil-1,2,3,4,4a,10b-heksahidro-6-(4-diizopropilaminokarbonilfenil)-benzo[c][1,6]naftiridina [INN: PUMAFENTRIN] i njihovih farmaceutski prihvatljivih derivata, i druge aktivne supstance, koja je odabrana iz grupe koja se sastoji od (plus/minus)-[2-[4-(p-hloro-alfa-fenilbenzil)-1-piperazinil]etoksi]-sirćetne kiseline [INN: CETIRIZIN] i njegovih famraceutski prihvatljivih derivata.Prijava sadrži još 16 patentnih zahteva.
YUP-780/04A 2002-03-06 2003-02-25 Farmaceutska kompozicija inhibitora pde4 ili inhibitora pde3/4 i antagoniste histamiinskih receptora RS51018B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02004987 2002-03-06
PCT/EP2003/001876 WO2003074055A1 (en) 2002-03-06 2003-02-25 Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist

Publications (2)

Publication Number Publication Date
RS78004A RS78004A (en) 2006-12-15
RS51018B true RS51018B (sr) 2010-10-31

Family

ID=27771841

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-780/04A RS51018B (sr) 2002-03-06 2003-02-25 Farmaceutska kompozicija inhibitora pde4 ili inhibitora pde3/4 i antagoniste histamiinskih receptora

Country Status (32)

Country Link
US (1) US20050112069A1 (sr)
EP (2) EP1849468B1 (sr)
JP (1) JP5150034B2 (sr)
KR (1) KR20040095255A (sr)
CN (1) CN101257904A (sr)
AR (1) AR038858A1 (sr)
AT (1) ATE369134T1 (sr)
AU (1) AU2003212268B2 (sr)
BR (1) BR0308220A (sr)
CA (1) CA2478612C (sr)
CO (1) CO5611148A2 (sr)
CY (2) CY1106927T1 (sr)
DE (1) DE60315426T2 (sr)
DK (2) DK1482938T3 (sr)
EA (2) EA010886B1 (sr)
ES (2) ES2291618T3 (sr)
HK (1) HK1071308A1 (sr)
HR (1) HRP20040909B1 (sr)
IL (1) IL163336A (sr)
IS (2) IS2536B (sr)
MX (1) MXPA04008460A (sr)
NO (1) NO335254B1 (sr)
NZ (1) NZ535611A (sr)
PL (1) PL211574B1 (sr)
PT (2) PT1849468E (sr)
RS (1) RS51018B (sr)
SG (1) SG160197A1 (sr)
SI (2) SI1849468T1 (sr)
TW (1) TWI347845B (sr)
UA (1) UA80117C2 (sr)
WO (1) WO2003074055A1 (sr)
ZA (1) ZA200407104B (sr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1956906A4 (en) * 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
DE602007005167D1 (de) * 2006-12-20 2010-04-15 Glaxo Group Ltd 4-benzyl-1(2h)-phthalazinone als h1-rezeptor-antagonisten
TW200902025A (en) * 2007-04-11 2009-01-16 Alcon Res Ltd Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
US8877816B2 (en) 2007-11-21 2014-11-04 Decode Genetics Ehf 4-(or 5-) substituted catechol derivatives
KR20090061972A (ko) * 2007-12-12 2009-06-17 한미약품 주식회사 베포타스틴 ｐ-톨루엔술폰산염의 결정형, 이의 제조방법 및이를 포함하는 약학 조성물
ME02598B (me) 2011-02-07 2017-06-20 Scipharm Sarl Nova kompozicija za lečenje cistične fibroze
KR102226833B1 (ko) * 2013-06-28 2021-03-12 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형
JP2017525721A (ja) * 2014-08-26 2017-09-07 ファンダシオン パラ ラ インベスティガシオン メディカ アプリカダＦｕｎｄａｃｉｏｎ Ｐａｒａ Ｌａ Ｉｎｖｅｓｔｉｇａｓｉｏｎ Ｍｅｄｉｃａ Ａｐｌｉｃａｄａ 認知欠損または認知障害に伴って進行する神経障害のおよび神経変性疾患の処置および予防のための製品
SG11201702900SA (en) 2014-10-09 2017-05-30 Guangdong Zhongsheng Pharmaceutical Co Ltd Hydroxyl purine compounds and applications thereof
CN109956947A (zh) * 2017-12-25 2019-07-02 江苏恒瑞医药股份有限公司 一种cns抑制剂的新晶型、制备方法及用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
AU687087B2 (en) * 1993-07-02 1998-02-19 Takeda Gmbh Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5990147A (en) * 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
BR9804993A (pt) * 1998-11-10 2000-06-06 Panacea Biotec Ltd Composição antialérgica e antiinflamatória
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
IL148807A0 (en) * 1999-10-25 2002-09-12 Byk Gulden Lomberg Chem Fab Tetrahydrothiopyran derivatives and pharmaceutical compositions containing the same
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
GB0115181D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use

Also Published As

Publication number Publication date
PL371056A1 (en) 2005-06-13
IS7438A (is) 2004-09-03
CY1113894T1 (el) 2016-07-27
EP1482938A1 (en) 2004-12-08
UA80117C2 (uk) 2007-08-27
EA200401137A1 (ru) 2005-04-28
PT1482938E (pt) 2007-11-15
SI1849468T1 (sl) 2013-03-29
ES2400670T3 (es) 2013-04-11
AU2003212268B2 (en) 2008-09-11
NZ535611A (en) 2006-03-31
CY1106927T1 (el) 2012-09-26
DE60315426T2 (de) 2008-07-03
US20050112069A1 (en) 2005-05-26
CO5611148A2 (es) 2006-02-28
WO2003074055A1 (en) 2003-09-12
EA007903B1 (ru) 2007-02-27
EP1849468B1 (en) 2012-12-05
KR20040095255A (ko) 2004-11-12
EA200601592A1 (ru) 2006-12-29
SI1482938T1 (sl) 2007-12-31
TW200306855A (en) 2003-12-01
CA2478612A1 (en) 2003-09-12
DK1849468T3 (da) 2013-02-04
DE60315426D1 (de) 2007-09-20
AR038858A1 (es) 2005-01-26
CA2478612C (en) 2013-12-10
EP1849468A3 (en) 2007-11-07
CN101257904A (zh) 2008-09-03
SG160197A1 (en) 2010-04-29
EP1849468A2 (en) 2007-10-31
IS8760A (is) 2008-09-04
ATE369134T1 (de) 2007-08-15
JP2005524666A (ja) 2005-08-18
DK1482938T3 (da) 2007-12-03
EA010886B1 (ru) 2008-12-30
RS78004A (en) 2006-12-15
HRP20040909B1 (en) 2012-11-30
EP1482938B1 (en) 2007-08-08
TWI347845B (en) 2011-09-01
NO20044230L (no) 2004-12-06
ZA200407104B (en) 2006-12-27
ES2291618T3 (es) 2008-03-01
IL163336A (en) 2009-02-11
PT1849468E (pt) 2013-02-27
NO335254B1 (no) 2014-10-27
AU2003212268A1 (en) 2003-09-16
IS2536B (is) 2009-08-15
PL211574B1 (pl) 2012-05-31
MXPA04008460A (es) 2004-12-06
JP5150034B2 (ja) 2013-02-20
HRP20040909A2 (en) 2005-08-31
HK1071308A1 (en) 2005-07-15
BR0308220A (pt) 2005-01-04

Similar Documents

Publication Publication Date Title
ME00318B (me) Nova kompozicija i njena upotreba
AR030190A1 (es) Una pirimidinona o una sal farmaceuticamente aceptable de la misma, composicion farmaceutica que la comprende, uso de dicho compuesto en la fabricacion de medicamentos y procedimiento para prepararlo
ATE257703T1 (de) 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
DK1499607T3 (da) 4-(piperidyl- og pyrrolidyl-alkyl-ureido)-quinoliner som urotensin II-receptorantagonister
ES2192264T3 (es) Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2(1h)-indol-2-ona (=ziprasidona), su preparacion y su uso como antagonista de la dopamina.
BRPI0116237B8 (pt) "composto de sulfamida, composição farmacêutica contendo o mesmo e seu uso como medicamento antagonista de receptor de endotelina".
HRP20020158B1 (en) Action of synergistic combination
ATE204857T1 (de) Meta-substituierte phenylenderivate und ihre verwendung als alphavbeta3 intergrin-antagonisten oder inhibitoren
DK1076644T3 (da) N-Substituerede aminotetraliner som ligander for neutopeptid Y Y5-receptoren, der er nyttig til behandling af fedme og andre lidelser
EA200501586A1 (ru) Фармацевтические продукты
WO2003004480A3 (en) Substituted piperazine and diazepanes as histamine h3 receptor agonists
DK0891325T3 (da) Para-substituerede phenylpropansyrederivater som integrinantagonister
NO20042161L (no) Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
RS51018B (sr) Farmaceutska kompozicija inhibitora pde4 ili inhibitora pde3/4 i antagoniste histamiinskih receptora
ATE516016T1 (de) Selbstemulgierende formulierungen von cetp- hemmern
EP1630157A4 (en) ANTAGONIST OF CASR
WO2001096307A3 (en) Cycloalkyl alkanoic acids as integrin receptor antagonists
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
WO2005092307A3 (en) Pharmaceutical dosage forms and compositions of 5-ht1a receptor antagonists
ATE454385T1 (de) Hiv-integrase-hemmers, pharmazeutischen zusammensetzung und ihre anwendung
WO2004014868A3 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
HRP20090190T1 (en) Pharmaceutical composition comprising a salt of mirtazapine